Vabysmo for wet AMD shows good visual acuity, anatomic outcomes in real-world study
Click Here to Manage Email Alerts
NEW YORK — A real-world study showed that Vabysmo helps improve visual acuity and anatomic parameters in patients with neovascular age-related macular degeneration.
Carl J. Danzig, MD, FASRS, presented results from the TRUCKEE study at the American Society of Retina Specialists annual meeting. The study explored the efficacy and safety of Vabysmo (faricimab, Genentech) in real-world patients with neovascular AMD.
“Our target population was treatment-naive but mostly hard-to-treat patients, the ones who are high need,” he said.
The study comprised 421 eyes of 377 patients for a total of 770 intravitreal injections. Follow-up data from 236 eyes were available for analysis.
The study eyes had a mean of 63.3 ETDRS letters at follow-up, a mean improvement of 0.5 letters from baseline. Improvements were observed in central subfield thickness and pigment epithelium detachment height, and visual and anatomical improvements were similar in patients who switched from any anti-VEGF treatment.
Danzig said the safety outcomes have been good. No cases of intraocular inflammation, retinal vasculitis or retinal artery occlusion have been reported. One case of endophthalmitis resolved with treatment.
“TRUCKEE is an ongoing collaborative study,” Danzig said. “Based on this very early experience, faricimab has shown efficacy in both difficult-to-treat and treatment-naive patients.”
Collapse
Danzig CJ, et al. The TRUCKEE study: Real world efficacy and safety of faricimab in neovascular AMD. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Read more about
Click Here to Manage Email Alerts